Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - US45773H4092 - Common Stock

2.37 USD
-0.09 (-3.66%)
Last: 8/29/2025, 8:00:02 PM
2.38 USD
+0.01 (+0.42%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, INO scores 2 out of 10 in our fundamental rating. INO was compared to 542 industry peers in the Biotechnology industry. INO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, INO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.
INO had a negative operating cash flow in the past year.
INO had negative earnings in each of the past 5 years.
INO had a negative operating cash flow in each of the past 5 years.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of INO (-128.61%) is worse than 82.47% of its industry peers.
With a Return On Equity value of -307.60%, INO is not doing good in the industry: 71.40% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -128.61%
ROE -307.6%
ROIC N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INO has more shares outstanding
INO has more shares outstanding than it did 5 years ago.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

INO has an Altman-Z score of -38.74. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
INO has a Altman-Z score of -38.74. This is amonst the worse of the industry: INO underperforms 90.96% of its industry peers.
INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.74
ROIC/WACCN/A
WACC9.84%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

INO has a Current Ratio of 1.66. This is a normal value and indicates that INO is financially healthy and should not expect problems in meeting its short term obligations.
INO has a Current ratio of 1.66. This is in the lower half of the industry: INO underperforms 79.52% of its industry peers.
INO has a Quick Ratio of 1.66. This is a normal value and indicates that INO is financially healthy and should not expect problems in meeting its short term obligations.
INO's Quick ratio of 1.66 is on the low side compared to the rest of the industry. INO is outperformed by 78.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

INO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.54%, which is quite impressive.
The Revenue for INO has decreased by -69.20% in the past year. This is quite bad
Measured over the past years, INO shows a very negative growth in Revenue. The Revenue has been decreasing by -44.44% on average per year.
EPS 1Y (TTM)51.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.74%
Revenue 1Y (TTM)-69.2%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 17.13% on average over the next years. This is quite good.
INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 356.19% yearly.
EPS Next Y52.28%
EPS Next 2Y27.09%
EPS Next 3Y22.34%
EPS Next 5Y17.13%
Revenue Next Year-30.68%
Revenue Next 2Y949.07%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

INO's earnings are expected to grow with 22.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.09%
EPS Next 3Y22.34%

More info and screens

0

5. Dividend

5.1 Amount

INO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (8/29/2025, 8:00:02 PM)

After market: 2.38 +0.01 (+0.42%)

2.37

-0.09 (-3.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-12 2025-11-12
Inst Owners27.07%
Inst Owner Change-25.93%
Ins Owners0.54%
Ins Owner Change1.65%
Market Cap125.94M
Analysts80
Price Target7.62 (221.52%)
Short Float %9.64%
Short Ratio2.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.92%
Min EPS beat(2)0.86%
Max EPS beat(2)44.99%
EPS beat(4)4
Avg EPS beat(4)24.57%
Min EPS beat(4)0.86%
Max EPS beat(4)44.99%
EPS beat(8)5
Avg EPS beat(8)9.12%
EPS beat(12)7
Avg EPS beat(12)8.41%
EPS beat(16)8
Avg EPS beat(16)0.48%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.44%
PT rev (3m)-4.68%
EPS NQ rev (1m)14.88%
EPS NQ rev (3m)24.43%
EPS NY rev (1m)7.09%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)10.13%
Revenue NY rev (3m)-97.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 690.85
P/FCF N/A
P/OCF N/A
P/B 4.41
P/tB 4.41
EV/EBITDA N/A
EPS(TTM)-2.51
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-1.79
FCFYN/A
OCF(TTM)-1.78
OCFYN/A
SpS0
BVpS0.54
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.61%
ROE -307.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.69%
ROA(5y)-69.23%
ROE(3y)-132.51%
ROE(5y)-101.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.98%
Cap/Sales 49.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -38.74
F-Score1
WACC9.84%
ROIC/WACCN/A
Cap/Depr(3y)16.84%
Cap/Depr(5y)25.5%
Cap/Sales(3y)90.66%
Cap/Sales(5y)72.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.74%
EPS Next Y52.28%
EPS Next 2Y27.09%
EPS Next 3Y22.34%
EPS Next 5Y17.13%
Revenue 1Y (TTM)-69.2%
Revenue growth 3Y-50.31%
Revenue growth 5Y-44.44%
Sales Q2Q%-100%
Revenue Next Year-30.68%
Revenue Next 2Y949.07%
Revenue Next 3Y735.89%
Revenue Next 5Y356.19%
EBIT growth 1Y18.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.14%
OCF growth 3YN/A
OCF growth 5YN/A